Figure 2: Schematic diagram indicating the plausible anti-cancer activity of ellagic acid. Modulation of targets from various cancer hallmarks by ellagic acid. Targets up-regulated is suffixed by ↑, those down-regulated are suffixed by ↓. TGF-β1 transforming growth factor beta, PDGF platelet derived growth factor, CDK2 cyclin dependent kinase 2, CCNA2 cyclin A2, CCNB1 cyclin B1, CCND1 cyclin D1, PKCα protein kinase C alpha, Bax bcl2-associated X protein, p53 tumor protein p53, Bcl-xL bcl2-like 1, Akt v-akt murine thymoma viral oncogene homolog 1, NF-κβ Nuclear factor-kappa B, c-Myc v-myc myelocytomatosis viral oncogene homolog (avian), p21 cyclin-dependent kinase inhibitor 1A (p21, Cip1), CK2 Casein kinase 2, TERT Telomerase reverse transcriptase, IL-1 beta interleukin 1, beta, TNF-alpha tumor necrosis factor, MMP9 matrix metalloproteinase 9, MMP3 matrix metalloproteinase 3, COX-2 prostaglandinendoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), VEGF vascular endothelial growth factor.